» Articles » PMID: 14604549

Levels of Mannan-binding Lectin-associated Serine Protease-2 in Healthy Individuals

Overview
Publisher Elsevier
Date 2003 Nov 8
PMID 14604549
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

The lectin pathway is part of the innate immune system providing a first line of defence against infections. Mannan-binding lectin (MBL) and ficolins, in complex with MBL-associated serine proteases (MASPs), are capable of activating the complement system, thus mediating the destruction of infectious agents. MASP-2 cleaves C4 and C2 and is thus crucial for the activation of downstream complement components. We present an assay for quantifying total MASP-2 in plasma and serum samples. The assay is a sandwich type assay using a combination of two monoclonal anti-MASP-2 antibodies, one directed against the N-terminal part of MASP-2 and the other against its C-terminal part. Based on a population of Danish blood donors, the average MASP-2 concentration was estimated at 534 (S.D.+/-213) ng per ml of plasma. Characterization of the MASP-2 protein in serum showed high stability at 4 degrees C and at ambient temperature but a rapid decline at 37 degrees C. Gel permeation chromatography (GPC) indicated that all MASP-2 in serum is present in complexes with MBL and ficolins.

Citing Articles

Complement proteins in axial spondyloarthritis: associations with disease activity and TNFi treatment response in a multicentre RCT.

Mistegaard C, Troldborg A, Torgutalp M, Loft A, Thiel S, Muche B Rheumatol Adv Pract. 2025; 9(1):rkaf007.

PMID: 39959130 PMC: 11825385. DOI: 10.1093/rap/rkaf007.


Revisiting the interaction between complement lectin pathway protease MASP-2 and SARS-CoV-2 nucleoprotein.

Bally I, Drumont G, Rossi V, Guseva S, Botova M, Reiser J Front Immunol. 2024; 15:1419165.

PMID: 38911852 PMC: 11190312. DOI: 10.3389/fimmu.2024.1419165.


Exploring complement biomarkers in suspected axial spondyloarthritis.

Mistegard C, Troldborg A, Loft A, Thiel S, Spiller L, Protopopov M RMD Open. 2024; 10(2).

PMID: 38749532 PMC: 11328660. DOI: 10.1136/rmdopen-2024-004127.


Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.

Schoettler M, Patel S, Bryson E, Deeb L, Watkins B, Qayed M Transplant Cell Ther. 2023; 30(3):336.e1-336.e8.

PMID: 38145741 PMC: 11163410. DOI: 10.1016/j.jtct.2023.12.017.


Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders.

Dudler T, Yaseen S, Cummings W Front Immunol. 2023; 14:1297352.

PMID: 38022610 PMC: 10663225. DOI: 10.3389/fimmu.2023.1297352.